Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta‐analysis of controlled studies
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14232 ↗At a glance
Metaanalyse in European Journal of Clinical Investigation, 2024. Written by Ghazaleh Nameni and 4 co-authors. Institution: Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. Major MEDLINE topics: Biomarkers, Mental Disorders, Neurocognitive Disorders, Receptor for Advanced Glycation End Products. Cited 7 times so far (Crossref); 56 references.
Abstract (original language)
Background & Objectives Currently, there is a significant focus on the decrease of soluble receptor of advanced glycation end products (sRAGE) in neurocognitive and neuropsychiatric disorders. sRAGE plays a decoy role against the inflammatory response of advanced glycation end products (AGE), which has led to increased interest in its role in these disorders. This meta‐analysis aimed to investigate the significant differences in sRAGE levels between neurocognitive and neuropsychiatric disorders compared to control groups.
Method
A systematic review was conducted using the PUBMED, Scopus and Embase databases up to October 2023. Two reviewers assessed agreement for selecting papers based on titles and abstracts, with kappa used to measure agreement and finally publications were scanned according to controlled studies. Effect sizes were calculated as weighted mean differences (WMD) and pooled using a random effects model. Heterogeneity was assessed using I 2 , followed by subgroup analysis and meta‐regression tests. Quality assessment was performed using the Newcastle‐Ottawa Quality Assessment Scale.
Results
In total, 16 studies were included in the present meta‐analysis. Subjects with neurocognitive ( n = 1444) and neuropsychiatric ( n = 444) disorders had lower sRAGE levels in case–control (WMD: −0.21, 95% CI: −0.33, −0.10; p 50 years (WMD: −0.33, 95% CI: −0.54, −0.13, p = 0.000) and in Asian countries (WMD: −0.28, 95% CI: −0.42, −0.13, p =.141) had lower sRAGE levels in cross‐sectional studies.
Conclusion
This meta‐analysis revealed a significant reduction in sRAGE in neurocognitive and neuropsychiatric disorders particularly in Asians and moderate age.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
- Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Department of Nutrition, Faculty of Public Health Branch, Iran University of Medical Sciences, Tehran, Iran.
ORCID profiles: Ghazaleh Nameni, Somaye Fatahi
Cite
APA
Nameni, G., Jazayeri, S., Fatahi, S., Jamshidi, S., & Zaroudi, M. (2024). Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta‐analysis of controlled studies. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14232
Vancouver
Nameni G, Jazayeri S, Fatahi S, Jamshidi S, Zaroudi M. Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta‐analysis of controlled studies. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14232
BibTeX
@article{Nameni2024,
author = {Nameni, Ghazaleh and Jazayeri, Shima and Fatahi, Somaye and Jamshidi, Sanaz and Zaroudi, Marsa},
title = {Soluble receptor of advanced glycation end product as a biomarker in neurocognitive and neuropsychiatric disorders: A meta‐analysis of controlled studies},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14232}
}
EUVIMED